Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use 

ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton

Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the publication of an independent, researcher-led peer-reviewed study demonstrating the potential for individuals with chronic spinal cord injury to use a personal exoskeleton to perform everyday activities while standing in their homes.